INFORMACIONES PSIQUIÁTRICAS 247

96 Informaciones Psiquiátricas 2022 - n.º 247 19. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol 2018; 8: 303–18. 20. Cunningham Owens DG. A guide to the extrapyramidal side- effects of antipsychotic drugs, 2nd edn. Cambridge: Cambridge University Press, 2014. 21. Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am 2007; 30: 511–33 22. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96 23. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second- generation versus first-generation antipsychotic drugs for schi- zophrenia: a meta-analysis. Lancet 2009; 373: 31–41. 24. NICE. Psychosis and schizophrenia in adults: treatment and ma- nagement. National Clinical Guideline Number 178. London: Na- tional Collaborating Centre for Mental Health/National Institute for Health and Care Excellence, 2014. 25. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophre- nia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 2014; 204: 20–29. 26. van Os J, Hanssen M, Bijl RV, Ravelli A. Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res 2000; 45: 11–20. 27. Johns LC, van Os J. The continuity of psychotic experiences in the general population. Clin Psychol Rev 2001; 21: 1125–41. 28. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime pre- valence, demographic risk factors, and diagnostic validity of FIDMAG informa